{
    "organizations": [],
    "uuid": "cd179c8a09f6b3cb55c792a0b998e03c8d2c3063",
    "author": "",
    "url": "https://www.reuters.com/article/brief-exelixis-announces-amendment-to-pr/brief-exelixis-announces-amendment-to-protocol-for-phase-1b-trial-of-cabozantinib-in-combination-with-atezolizumab-idUSFWN1OZ0PV",
    "ord_in_thread": 0,
    "title": "BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 1:09 PM / Updated 7 minutes ago BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab Reuters Staff \nJan 4 (Reuters) - Exelixis Inc: \n* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB \n* EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T15:08:00.000+02:00",
    "crawled": "2018-01-04T15:28:09.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "amendment",
        "protocol",
        "phase",
        "1b",
        "trial",
        "cabozantinib",
        "combination",
        "atezolizumab",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "inc",
        "amendment",
        "protocol",
        "phase",
        "1b",
        "trial",
        "cabozantinib",
        "combination",
        "atezolizumab",
        "exelixis",
        "inc",
        "amendment",
        "add",
        "four",
        "new",
        "expansion",
        "cohort",
        "phase",
        "1b",
        "trial",
        "include",
        "patient",
        "nsclc",
        "crpc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}